waiting game.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well every company has a different philosophy. To be fair MDIN isn't diluting the company themselves. Rather, the group that provided them financing has a big price tag to dump on the shareholders and they get the shares at a discount price so they really don't care about the PPS.
He has to go in ballistic overtime to get people to keep buying this company right now. I feel for him but at the same time I'm not going to buy it just because he tells me to.
Hello .0001!
Time for my buy order =)
141 million sells.. almost all dillution. Come on now.
That isn't evidence that they don't have to though. It just states that they haven't.
Wait, isn't there a difference in being a SEC reporting company and reporting TO the SEC?
I'm pretty sure (and pennystock halts testify to this) that there are some documents that must be filled with the SEC regardless of their status.
That really isn't grounded in truth. The only requirement for a tender offer that would be seen by shareholders is the notification of the offer, which is where you got your .01/share statement from =).
It would make sense this is the reason he wasn't at the conference call. He's not the president of the US though, he could have told us he was sick :P.
Pneumonia is hard to get rid of when your older. Especially if you already have existing problems or let it go untreated for long enough. He should be glad he didn't die.
That however, would mean the end of the deal and while I would be sorry at the loss of a human being, I would have the first case of pennystock induced death.
I must say I am impressed with people that are willing to stick this out. I got burned a bit on the drop after the conference weeks ago and I don't think I want to be on board for another one. I really hope this works out for everyone and I'll be watching in case its positive news. Hopefully I can jump on the bandwagon :P
"After all if you guys all believe in me and what I have going here, wouldn't it be smart to diversify into another similar situation? And vice-versa?"
A penny stock hedgefund. Will the amazon book futures be the financial derivatives? :P
Doubtful. For such a "clear and honest" CEO he sure has some ambiguous PRs.
Not until we break .40
A partial order?
"Cablevision that will allow the firm to leverage the client base of the Cable company"
What does that even mean?
Sigh.
Tomorrow or Wednesday, given history. If you are smart you will load up on .0002's now and sell the second it hit's .0003. If you hold out for 4's you are risking being crushed by the dilution machine that will start after the PR.
More sleeping this week?
If. If. If.
They have signed deals to sell these properties but have made no sales. So, it's not fair to say they are going to be or are one of the most profitable companies in the pinks.
They have to be able to sell and if they were going to be selling anytime soon he wouldn't be trying to procure a book distributor. Because when I think huge corporate business broker, I think books on Amazon.
Post Unavailable
Additional Information
He needs to tell the truth that NIR Group has MDIN by the throat and they get whatever they want. He is just their puppet and doing a wonderful job at helping them have buyers for the dillution.
So now he is down to attacking his own investors? That's professional.
A CEO never sleeps? How about a CEO never works to begin with :P
It usually bounces off of .0012 back to around .002.
I don't think PPS is going much beyond .002 until they get some real data out. As their recent activity with SEC halts has shown, the minarmar companies are lacking in real data. It's a lot of fluff and promises which in SKGOs case investors have not responded well to. We were promised a real company and need to see some real results.
Post Unavailable
Additional Information
To be fair the SEC halted them because they haven't provided any information to them. That's it. Other things may come out now but don't go tooting your horn just yet :P
Post Unavailable
Additional Information
He's good at what he does, have your order in as soon as the next PR comes out next week. If you can get your sell in before the dilution machine you should be fine.
No, it just means the company has to issue them shares to sell for them =).
42 blocks of 9 million
The bad news? That's only $113,400
And when is the last time SKGO filled with the SEC?
1 year, 7 months, 24 days..
I guess its time to spend money on a securities lawyer to actually make this merger legitimate.
If I cared about this stock enough I would go back over the last month and show you all this exact pattern. They dillute all the time except during PRs. That gives the illusion of a rising PPS. Then the next day they bring heavy dilution in and the CEO will be on his little blog preaching to the heavens about how you should trust him --- and get your friends to invest. It's a long road to 6 million @ 55%.
Well in theory, that is supposed to be the purpose of them getting in with IB. Then they would have access to a network of brokers but they can't really apply for anything. I think if we went to Errol right now and asked him to show us trade-tablet he would break out a piece of paper with arrows on it showing a concept design.
If I could afford the annoyance of filling with SEC, I think I could generate a more legitimate pink sheet company that does nothing better than him. Maybe the ONCP investors will support by monthly salary as well.
"real" traders don't look at companies in the triple zeros :)
I think the big gap is scaring a lot of people right now. ARGC is at pretty high levels compared to previous history.
They evidently have a big PR campaign and I've seen a lot more people starting to pick up ARGC. The problem is getting those first few people to get the volume rolling. Unfortunately those few people have already come and are sitting on their investment. As far as I can tell the only sells coming in are the shorts taking positions.
This PR was good but I'm hoping the next announces a more concrete contract involving revenues. 1.5 million is nothing to balk at but that is almost insignificant in the pharmaceutical industry. FDA approval would be a waste of money but if they could get other western organizations to support Artequick it would help things along.
A blog is very informal. I don't even know how that works legally with the SEC. That being said he can delete all of that information in seconds with little to no trace it ever existed.
This is definitely one for the books. He's either the best con artist I've seen on the pinks or he really does believe everything he says. I'm going to go with the former. PPS speaks for itself.
Just wait, when the PPS downticks to .0001 they will throw out another PR. Be ready.
Yes, now add in all the other tranches NIR has given to MDIN. MDIN has not accounted for any forgiven debt on their financial statements. So maybe this ecstatic CEO should head on over to the accounting department and work his magic on those numbers.
Big news! Annnd down 27%
I'm thinking these are people who have been stuck in ARGC or people who got on board and are selling prematurely. I'm definitely hanging on until I see a few more PRs.
yeah at this rate they will be able to dilute those 3 billion in shares in no time. I can't believe people miss this pattern...this is like the 6th time it has happened. They release news, do a little bit of dillution, the stock still goes up. The rest of the week they dilute the jesus out of it, then release more news...
ARGC News, Joint Venture With Chinese Pharmaceutical Company to Market an Inexpensive and Quick-Acting Malaria Cure. Should see some nice momo tomorrow.
Artepharm Announces Joint Venture With Chinese Pharmaceutical Company to Market an Inexpensive and Quick-Acting Malaria Cure
Artepharm Global Corp. (the "Company") (OTCBB: ARGC) (www.artepharmglobal.com) is pleased to announce a joint venture with Artepharm Co. Ltd. (Artepharm China), a mid-sized pharmaceutical and biotech company based in Guangzhou, China, who have successfully developed and patented a drug that is effective as both a malaria cure and prevention method.
The anti-malarial drug, Artequick®, is currently being marketed in 11 countries where the incident rate of malaria is high. This is an affordable four-pill treatment, which is sufficient to both cure and prevent even the latest strains of malaria. For 2009, Artepharm China generated approximately US$1.5 million. Under the terms of the joint venture, Artepharm Global will acquire the global marketing rights and hold the global patents for the drug Artequick®, as well as retain all the revenues generated from continuing sales in exchange for 40 million shares of the Company.
The Artequick® anti-malarial drug was developed as a highbred of Chinese natural medicine and modern western pharmaceutical technology. The active ingredient in Artequick® is artemisinin, a plant that is indigenous to China and has been utilized as malaria treatment since the 1600's. While artemisinin has its roots in traditional Chinese medicine, the Artequick® delivery system was developed using the latest in modern western pharmaceutical technology. This integration of eastern and western medicine is a new approach to developing efficacious drugs and could mark the beginning of a massive shift in the global pharmaceutical industry.
In March 2009, the TV news show Dateline (Australia) aired an 18-minute documentary on Artepharm China's work in eradicating malaria on the island of Moheli, in the Comoros Islands off the east coast of Africa. Just months after the Moheli project was launched in November 2007, the island's malaria infection rate dropped rapidly from 22% to 2%. Within the year leading up to this documentary, there were no deaths attributed to malaria. The full documentary can be viewed at http://www.sbs.com.au/dateline/story/about/id/600026/n/The-Last-Bite or on our website at www.artepharmglobal.com.
Malaria infects over half a billion people each year and causes 3,000 deaths a day. With over 40% percent of the world's population living in areas where malaria is endemic, the vast majority also living in a state of poverty, the market for an inexpensive malaria cure is immeasurable and Artequick® is an optimal solution. Artepharm Global is positioned to positively alter the effect malaria has on the world today.
About Artepharm Global
Artepharm Global has acquired the patent and worldwide marketing rights for Artequick®, a natural artemisinin-based anti-malaria drug developed by Artepharm Co. Artepharm Co. is a modern pharmaceutical company involved in R&D and the manufacturing of artemisinin-based anti-malarias and anti-viral traditional Chinese medicines. It was jointly established by a group of experts specializing in the research of Qinghao, commonly known as Artemisia annua. For more information got to www.artepharmglobal.com.
Safe Harbour and Forward Looking Statements
Except for the statements of historical fact contained herein, the information presented in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans, "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and should be viewed as "forward-looking statements". Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labour disputes and other risks of the mining industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.
Forward looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports and registration statement filed with the United States Securities and Exchange Commission (the "SEC") (available at www.sec.gov) and with Canadian securities administrators (available at www.sedar.com). Such risks and uncertainties may include, but are not limited to, the risks and uncertainties set forth in the Company's filings with the SEC, such as the ability to obtain additional financing, the effect of economic and business conditions, the ability to attract and retain skilled personnel and factors outside the control of the Company. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the SEC. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the Company nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Contacts:
Artepharm Global Corp.
604-575-3552
604-575-3559 (FAX)
info@artepharmglobal.com
www.artepharmglobal.com